| __timestamp | Amphastar Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 20140000 |
| Thursday, January 1, 2015 | 46974000 | 37173000 |
| Friday, January 1, 2016 | 47298000 | 48616000 |
| Sunday, January 1, 2017 | 50918000 | 108488000 |
| Monday, January 1, 2018 | 58044000 | 244622000 |
| Tuesday, January 1, 2019 | 63109000 | 287000000 |
| Wednesday, January 1, 2020 | 65157000 | 354000000 |
| Friday, January 1, 2021 | 68920000 | 186000000 |
| Saturday, January 1, 2022 | 66592000 | 151000000 |
| Sunday, January 1, 2023 | 80393000 | 232600000 |
| Monday, January 1, 2024 | 267474000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Ionis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct strategies in handling these costs. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, starting from $40 million to $80 million. In contrast, Ionis saw a staggering increase of over 1,000%, with expenses rising from $20 million to $232 million.
While Ionis's expenses surged, Amphastar maintained a more consistent growth trajectory. This suggests that Amphastar might be more efficient in managing its operational costs, potentially giving it a competitive edge. However, Ionis's higher expenses could also indicate aggressive expansion and investment in growth. Understanding these dynamics is essential for investors and stakeholders looking to make informed decisions in the pharmaceutical sector.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.